Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 3, Issue 2, 1996, Pages 85-96

  Lin, R ^a   Liddle, C ^a   Byth, K ^a   Farrell, G C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Chronic HCV; Host determinants; Response; Virus

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; CHRONIC DISEASE; FEMALE; FOLLOW UP; GENETICS; HEPATITIS C; HUMAN; MALE; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; TIME; VIROLOGY;

CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MULTIVARIATE ANALYSIS; TIME FACTORS;

EID: 0030093219     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00086.x     Document Type: Article

References (52)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
2. Alter HJ. Hepatitis C virus and its relationship to the clinical spectrum of NANB hepatitis. J Gastroenterol Hepatol 1990; 5 (Suppl 1): 78-94.
3. Davis GL, Balart LA. Schiff ER and the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon-α. A multicenter, randomized, controlled trial. N Engl J Med 1989; 301: 1501-1506.
4. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
5. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicentre randomised controlled trial from France. Hepatology 1991; 13: 393-397.
6. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulin F, Ouzan D. Comparison of 1 or 3 MU of interferon α-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
7. Lin R, Schoeman MN, Craig PI, Bilous M, Grierson J, McDonald JA. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust NZ J Med 1991; 21: 387-392.
8. Douglas DD, Rakela J, Lin HJ, Hollinger FB, Taswell HF, Czaja AJ. Randomized controlled trial of recombinant α-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993; 38: 601-607.
9. Lin R, Zimmerman M, Roach E, Farrell GC. α-interferon 2b (IFN) in the treatment of chronic active hepatitis C: interim report of the first multicentre Australian trial. Hepatology 1992; 16: 75A.
10. Ferenci P, Vogel W, Pristatuz G et al. Treatment of chronic hepatitis non-A, non-B with recombinant interferon (r-IFN) α. Hepatology 1988; 8: 1268.
11. Di Bisceglie AM, Martin P, Kassianides C et al. A randomized, double-blind, placebo-controlled trial of recombinant human α-interferon therapy for chronic non-A, non-B (type C) hepatitis. J Hepatol 1990; 11: s36-s42.
12. Hess G. Treatment of chronic hepatitis C. J Hepatol 1991; 1: s17-s20.
13. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
14. Perez R, Pravia R, Linares, Rodriguez M, Lombrana JL, Suarez A. Response related factors in recombinant interferon α-2b treatment of chronic hepatitis C. Gut 1993; 34 (2 Suppl): s139-s140.
15. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon α-2b: Swedish experience. J Hepatol 1990; 11 (Suppl 1): s57-s62.
16. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L. A randomized controlled trial of interferon-α-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; 11 (Suppl. 1): s43-s49.
17. Uchida T, Taira M, Shikata T et al. Histological difference between complete responders and non-responders to interferon therapy of the livers of patients with chronic hepatitis C. Acta Pathol Jpn 1993; 43: 230-236.
18. Metreau JM. Results of long term interferon treatment in non-A non-B/C chronic active hepatitis. The French group for the study of NANB/C hepatitis treatment. Gut 1993; 34 (2 Suppl): s112-s113.
19. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during inteferon α therapy. Gastroenterology 1993; 104: 877-883.
20. Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Matsumoto T. Effect of lymphoblastoid α-interferon in patients with chronic hepatitis C having different genotypic subtype of hepatitis C virus. Gastroenterol Jpn 1993; 28 Suppl 5: 45-47.
21. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagai M. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-299.
22. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
23. Tsubota A, Chayama K, Arase Y, Koida I, Saitoh S, Ikeda K. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 1993; 8: 535-539.
24. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H. Genotypes and titres of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299-305.
25. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titre. Dig Dis Sci 1994; 39: 977-982.
26. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-1504.
27. Cha TA, Beall E, Irvine J et al. At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci USA 1992; 89: 7144-7148.
28. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherklock S. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-18.
29. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechet C. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
30. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
31. Davis GL, Lau JYN, Urdea MS, Neuwald PD, Wilber JC, Lindsay K. Quantitative detection of hepatitis C virus RNA with a solid phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19: 1337-1341.
32. Okamoto H, Okasada S, Sugiyama Y, Yotsumoto S, Tanaka T, Yoshizawa H. The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167-177.
33. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-238.
34. Berger SL, Wallace DM, Puskas RS, Eschenfeldt WH. Reverse transcriptase and its associated ribonuclease H: interplay of two enzymes activity controls the yield of single-stranded complementary deoxyribonucleic acid. Biochemistry 1983; 22: 2365-2372.
35. Bouaboula M, Legoux P, Pessegue B, Delpech B, Dumont X, Piechaczyk M. Standardization of MRNA titration using a polymerase chain reaction method involving coamplification with a multispecific internal control. J Biol Chem 1992; 267: 21 830-838.
36. Armitage PA, Berry G. Statistical Methods in Medical Research. 2nd edn. Oxford: Blackwell Scientific Publications, 1987.
37. Davis GL, Lindsay K, Albrecht J and the Hepatitis Interventional Therapy Group. Clinical predictors of response to recombinant inteferon-α treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepatitis 1994; 1: 55-63.
38. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon α: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-1717.
39. Camps J, Garcia-Granero M, Riezu-Boj JI, Larrea E, de Alava E, Civeira MP, Prieto J. Prediction of sustained remission of chronic hepatitis C after a 12-month course of α interferon. J Hepatol 1994; 21: 4-11.
40. Margin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L. Hepatitis C viraemia in chronic liver disease: relationship to interferon-α or corticosteroid treatment. Hepatology 1994; 19: 273-279.
41. Watanabe S, Kobayashi Y, Konishi M et al. Appropriate interferon-α therapy for chronic hepatitis C: an assessment by quantitative changes in serum hepatitis C virus RNA. Intern-Med 1993; 32: 523-529.
42. Bresters D, Cuypers HTM, Reesink HW, Mauser-Bunschoten EP, Van den Berg HM, Schaasberg WP. Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial. J Med Virol 1994; 43: 262-268.
43. Nakagawa H, Shimomura H, Hasui T, Tsuji H, Tsuji T. Quantitative detection of hepatitis C virus genome in liver tissue and circulation by compeitive reverse-transcription polymerase chain reaction. Dig Dis Sci 1994; 39: 225-233.
44. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
45. Hagiwara H, Hayashi N, Mita E, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545-550.
46. Lindsay KL, Davis GL, Bodenheimer HC Jr, and the Hepatitis Interventional Therapy Group. Predictors of relapse and response to re-treatment in patients with an initial response to recombinant α interferon (rIFN) therapy for chronic hepatitis C. Hepatology 1990; 12: 847 (Abstr).
47. Pagliaro L, Craxi A, Cammaa C et al. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-828.
48. Alexander GJM, Brahm J, Fagan EA et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; ii: 66-69.
49. Benelux Multicentre Trial Study Group. Benelux multicentre trial of α interferon for chronic hepatitis C: standard vs high dose treatment monitored by biochemical and virological markers (interim analyis). Gut 1993; 34 (2 Suppl): s119-s120.
50. De Bac C, Grimaldi F, Clementi C, Duca F, Livoli D, Taliani G. Efficacy of different regimens of interferon α-2b treatment in chronic hepatitis C. Gut 1993; 34 (2 Suppl): s135.
51. Hoofnagle JH, Di Bisceglie AM, Shindo M. Antiviral therapy for hepatitis C - present and future. J Hepatol 1993; 17 (Suppl 3): 130-136.
52. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology 1994; 19: 280-285.